Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, currently in Phase II clinical trial for COVID-19 treatment. The company also develops other antiviral drugs for dengue, HCV, and other RNA viral infections. Atea has a license agreement with Merck & Co for the development and commercialization of ruzasvir for HCV treatment. The company was founded in 2012 and is based in Boston, Massachusetts.